The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma
10.3760/cma.j.cn501113-20200419-00197
- VernacularTitle:循环肿瘤DNA在肝细胞癌诊断和预后中作用的最新进展
- Author:
Zihao FAN
1
;
Feng REN
Author Information
1. 首都医科大学附属北京佑安医院 北京肝病研究所，北京 100069
- Keywords:
Hepatocellular carcinoma;
Circulating tumor DNA;
Circulating cell free DNA;
Methylation;
Diagnosis;
Prognosis
- From:
Chinese Journal of Hepatology
2022;30(12):1382-1386
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the common malignant tumors. However, the detection of biomarkers can't meet the clinical needs for the diagnosis and prognosis of HCC now. Circulating tumor DNA (ctDNA) is a highly tumor-specific DNA molecule that exists in the blood circulation. It is part of Circulating cell free DNA (cfDNA) and originates from the primary tumor or metastasis of cancer patients. Now, with the developing of next-generation sequencing technology and a full understanding of HCC genetics or epigenetic changes, we can analyze ctDNA mutations and methylation more comprehensively. Through continuous exploration of ctDNA mutations and methylation and continuous innovation of detection methods, HCC diagnosis and prognosis can be greatly improved in terms of specificity and sensitivity.
